title: Maillard reaction products in the Escherichia coli-derived therapeutic protein interferon alfacon-1.
abstract: We have recently shown that recombinant human interferon-gamma is affected by early stages of the Maillard reaction during its production in Escherichia coli. Over time, advanced glycation end products accumulated in the purified protein, accompanied with degradation, cross-linking, and a drop in the protein's biologic activity. Here, we provide further evidence for the presence of Maillard reaction products in another E. coli-derived therapeutic protein, interferon alfacon-1. These products might interfere with both treatment efficacy and patient safety.
authors: Department of Gene Regulations, Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria. rumym@bio21.bas.bg
authors: Roumyana
authors: R
authors: Mironova
authors: Angelina
authors: A
authors: Sredovska
authors: Ivan
authors: I
authors: Ivanov
authors: Toshimitsu
authors: T
authors: Niwa
mesh_terms: D015153:Blotting, Western; D004591:Electrophoresis, Polyacrylamide Gel; D004926:Escherichia coli; D007370:Interferon Type I / Q000032:analysis* / Q000737:chemistry* / Q000627:therapeutic use; D016898:Interferon-alpha; D015416:Maillard Reaction; D011994:Recombinant Proteins / Q000032:analysis / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; C050739:interferon alfacon-1